Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. The Food and Drug Administration is now requiring Biohaven to assess the potential for human toxicity from a metabolite in the drug, opakalim. Opakalim is in testing as a treatment for focal onset seizures.
Extract — continue reading at the source.
Related stories
How would Trump’s $5,000 voting payout work?
The 30-year mortgage rate just crossed 7% for the first time in over a year
Elon Musk is pulling in even more cash. Meet his $23 billion underground venture.
Brady Corp (BRC) Forecast $6.25 to $6.75 Adjusted EPS. Can Lower-Margin IPS Deliver Accretion?
OpenAI launches ChatGPT for Financial Services for Wall Street
The future of retirement: Work until you die